Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis

Open access
Mole, Damian J, Webster, Scott P, Uings, Iain, Zheng, Xiaozhong, Binnie, Margaret, Wilson, Kris, Hutchinson, Jonathan P, Mirguet, Olivier, Walker, Ann, Beaufils, Benjamin, Ancellin, Nicolas, Trottet, Lionel, Bénéton, Véronique, Mowat, Christopher G, Wilkinson, Martin, Rowland, Paul, Haslam, Carl, McBride, Andrew, Homer, Natalie Z M, Baily, James E, Sharp, Matthew G F, Garden, O James, Hughes, Jeremy, Howie, Sarah E M, Holmes, Duncan S, Liddle, John, Iredale, John P·2016·Nature Medicine

Abstract

Acute pancreatitis (AP) is a common and devastating inflammatory condition of the pancreas that is considered to be a paradigm of sterile inflammation leading to systemic multiple organ dysfunction syndrome (MODS) and death. Acute mortality from AP-MODS exceeds 20% (ref. 3), and the lifespans of those who survive the initial episode are typically shorter than those of the general population. There are no specific therapies available to protect individuals from AP-MODS. Here we show that kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism, is central to the pathogenesis of AP-MODS. We created a mouse strain that is deficient for Kmo (encoding KMO) and that has a robust biochemical phenotype that protects against extrapancreatic tissue injury to the lung, kidney and liver in experimental AP-MODS. A medicinal chemistry strategy based on modifications of the kynurenine substrate led to the discovery of the oxazolidinone GSK180 as a potent and specific inhibitor of KMO. The binding mode of the inhibitor in the active site was confirmed by X-ray co-crystallography at 3.2 Å resolution. Treatment with GSK180 resulted in rapid changes in the levels of kynurenine pathway metabolites in vivo, and it afforded therapeutic protection against MODS in a rat model of AP. Our findings establish KMO inhibition as a novel therapeutic strategy in the treatment of AP-MODS, and they open up a new area for drug discovery in critical illness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4020

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Mole, D. J., Webster, S. P., Uings, I., Zheng, X., Binnie, M., Wilson, K., Hutchinson, J. P., Mirguet, O., Walker, A., Beaufils, B., Ancellin, N., Trottet, L., Bénéton, V., Mowat, C. G., Wilkinson, M., Rowland, P., Haslam, C., McBride, A., Homer, N. Z. M., Baily, J. E., Sharp, M. G. F., Garden, O. J., Hughes, J., Howie, S. E. M., Holmes, D. S., Liddle, J., & Iredale, J. P.
Venue
Nature Medicine
Published
2016-01-11
Volume
22
Issue
2
Pages
202-209
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2234524284
Cited by
159
References
5
FWCI
19.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.